Anti-Depression CAS 138112-76-2 Agomelatine Material Agomelatine

• Customization: Available
• CAS No.: 138112-76-2
• Formula: C15h17no2
• Model NO.: QS-Agomelatine
• EINECS: 1312995-182-4
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: 2 Years
• Nutrient Composition: Agomelatine
• Resource: Agomelatine
• The content of active substances: 99%
• Product Name: Agomelatine
• Name: Agomelatine Powder
• Assay: HPLC 99%
• Appearance: White Powder
• Color: White
• Mf: C15h17no2
• MW: 243.3
• Melting Point: 107-109°c
• Boiling Point: 478.8
• Density: 1.109
• Test Method: HPLC
• Grade: Pharmaceutical Grade
• Application: Nootropics; Anti-Depression
• Specific: COA
• Pka: 16.17±0.46(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: QS
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Anti-Depression CAS 138112-76-2 Agomelatine Material Agomelatine

Product Description

Product Detials

Product Name	Agomelatine
Apperance	White Powder
CAS	138112-76-2
MF	C15H17NO2
MW	243.3

Agomelatine is a new type of antidepressant. Essentially, it has an excitatory effect on melatonin receptors and an antagonistic effect on serotonin receptors. It has multiple pharmacological effects such as anti-anxiety, anti-depression, regulating sleep rhythms, and regulating the biological clock. Clinically, it is often used to treat various neurological diseases such as depression, anxiety disorders, depression with sleep disorders, and sleep rhythm disorders. However, due to the special mechanism of action of agomelatine, its long-term use is prone to cause various adverse reactions, and the dosage needs to be individualized. It is recommended that patients in need take it scientifically under the guidance of a doctor.

Application&Function

Purpose
Active pharmaceutical ingredients for the nervous system. 

The melatonin analogue agomelatine is not only the first melatonin receptor agonist but also a 5-hydroxytryptamine 2C(S-HTx) receptor antagonist. Animal experiments and clinical studies have shown that this drug has the effects of anti-depression, anti-anxiety, regulating sleep rhythms and regulating biological clocks. Meanwhile, it has few adverse reactions, no adverse effects on sexual function, and no withdrawal reactions have been observed. Clinical studies have shown that agomelatine has a good therapeutic effect on patients with depression and has very few adverse reactions. Agomelatin [138112-76-2] was developed and manufactured by Servier and was approved for marketing in Europe in May 2009. The exact mechanism of agomelatine's antidepressant effect has not yet been clearly defined as 5-HT2C alone. Receptor blockers have no antidepressant effect. Agomelatine can block 5-HT2C. Receptors, however, animal experiments have shown that melatonin also has a small amount of antidepressant effect, and some studies have found that stress is related to the secretion of melatonin, but no obvious antidepressant effect has been observed in humans when taking melatonin. 

Specification

Certificate of Analysis